title: Intravitreal injection of bevacizumab in Eales disease.
abstract: OBJECTIVE
  To report a case of presumed Eales disease that showed regression of retinal neovascularization after the use of intravitreal bevacizumab.
  
  
  METHODS
  Retrospective, interventional case report.
  
  
  METHODS
  Broad retinal neovascularization in a patient with presumed Eales disease did not regressed despite adequate photocoagulation treatment, and bevacizumab (1.25 mg) was injected intravitreally. The patient was followed up for 1 year.
  
  
  RESULTS
  One week after injection, fluorescein angiography demonstrated dramatic regression of retinal neovascularization. After 12-months, visual acuity was improved and no signs of recurrence were observed.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab may be effective as an adjunctive treatment of retinal neovascularization in patients with Eales disease.
authors: Department of Ophthalmology, Baskent University Faculty of Medicine, Ankara, Turkey. drcemk@hotmail.com
authors: Cem
authors: C
authors: Küçükerdönmez
authors: Yonca A
authors: YA
authors: Akova
authors: Gürsel
authors: G
authors: Yilmaz
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000503:physiopathology; D012171:Retinal Vessels; D012189:Retrospective Studies; D016896:Treatment Outcome; D014657:Vasculitis / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab